Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Mucosal
Gingival hyperplasia/hypertrophy
(2004): Mesa F+, J Periodontal Res 39(1), 66
Sialorrhea
Eyes
Dyschromatopsia (blue-yellow)
(2000): Nousiainen I+, Ophthalmology I(5), 884
Ocular pain
Optic atrophy
(2003): Frisen L+, Acta Ophthalmol Scand 81(5), 466
(2003): Viestenz A+, Ophthalmologe 100(5), 402
Retinal atrophy
(2004): Buncic JR+, Ophthalmology 111(10), 1935 (3 cases)
Retinopathy
(2006): Kinirons P+, Epilepsia 47(2), 311
(2005): Hadjikoutis S+, Eur J Neurol 12(7), 499
(2005): Moraes MH+, Arq Neuropsiquiatr 63(2B), 469
(2003): Banin E+, Arch Ophthalmol 121(6), 811
(2003): McDonagh J+, Neurology 61(12), 1690
(2003): Morong S+, Doc Ophthalmol 107(3), 289
(2002): Jensen H+, Doc Ophthalmol 104(2), 171
(2001): Coupland SG+, Ophthalmology 108(8), 1493
Vision impaired
(2005): Best JL+, Eye 19(1), 41
(2005): Moreno MC+, Can J Neurol Sci 32(4), 459
(2004): Constable S+, Expert Opin Drug Saf 3(3), 249
(2003): Fledelius HC, Acta Ophthalmol Scand 81(1), 41
(2003): Hardus P+, Acta Ophthalmol Scand 81(5), 459
(2003): Mrugacz M+, Klin Oczna 105(5), 326
(2003): Riise P+, Ugeskr Laeger 165(10), 1034
(2002): Hilton EJ+, Epilepsia 43(11), 1351
(2002): Newman WD+, Eye 16(5), 567
(2002): van der Torren K+, Doc Ophthalmol 104(2), 181
Other
Abdominal pain (1.4%)
Hepatotoxicity
(2001): Locher C+, Gastroenterol Clin Biol 25(5), 556
VINBLASTINE
Trade names: Velban (Lilly); Velbe (Lilly); Velsar (Lilly)
Indications: Lymphomas, melanoma, carcinomas
Category: Antimitotic; Vinca alkaloid
Half-life: initial phase: 3.7 minutes; terminal phase: 24.8 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, aprepitant, erythromycin, fluconazole,
itraconazole, ketoconazole, miconazole
Reactions
Skin
Acne
Acral necrosis
(1998): Reiser M+, Eur J Clin Microbiol Infect Dis 17, 58
(1997): Hladunewich M+, J Rheumatol 24, 2371
Angioedema
(2003): Haas NB+, Cancer 98(9), 1837 (with estramustine)
Bullous dermatitis (10%)
Hair
Hair – alopecia (>10%)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 302 (passim)
Hair – changes (sic)
Other
Hypersensitivity
(2001): Mutafoglu-Uysal K+, Turk J Pediatr 43(2), 172
Inappropriate secretion of antidiuretic hormone (SIADH)
(1987): Fraschini G+, Tumori 73(5), 513 (3 cases)
(1983): Ravikumar TS+, JSurgOncol24(3), 242
(1982): Stahel RA+, Cancer Chemother Pharmacol 8(2), 253
(1980): Antony A+, JUrol123(5), 783
Injection-site extravasation
(2000): Kassner E, JPediatrOnconNurs17, 135
Injection-site necrosis
(1992): Misery L+, Presse Med (French) 21, 2153
(1991): Arias D+, JCutanPathol18, 344
Injection-site pain
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)
Nephrotoxicity
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with bleomycin &
vinblastine)